Imagine trying to study how blood flows through a vein, but your measuring tool is too clumsy to see the tiny changes. This technology creates a super-precise sensor for tiny channels that act like artificial blood vessels. It lets scientists mimic the human body much better than a petri dish or a lab animal could. This means we can test new medicines more accurately before they ever reach a patient.
Drug development is slowed by animal models that fail 90% of the time and a lack of precise flow sensors for microfluidic cell cultures. Current sensors are 100-times too narrow in range and suffer from drift, leading to experimental errors.
A wide-range microfluidic flow sensor (GALILEO) and a viable demonstrator for beta testing to accurately monitor and control fluid flow over cells.
If you are a drug discovery firm dealing with a 90% failure rate in animal models—this project developed a wide-range flow sensor that mimics human blood vessels. This allows for more physiologically relevant testing, potentially decreasing R&D costs by 10-26%.
If you are an organ-on-chip developer dealing with sensors that are 100-times too narrow in range—this project developed the GALILEO sensor to provide precise flow control. This enables the creation of viable demonstrators for beta testing of complex 3D cell cultures.
If you are a genomic medicine lab dealing with imprecise single-cell analysis—this project developed a sensor that detects drift and ensures precise fluid delivery. This supports the growth of next-generation sequencing and high-resolution cellular diagnostics.
Based on available project data, the specific unit price of the GALILEO sensor is not disclosed, though the project received an EU contribution of EUR 1,667,500 for development.
Yes, the project aims to advance a proof of concept to a viable demonstrator for beta testing, targeting a Serviceable Addressable Market (SAM) of 535 mil EUR/year.
Based on available project data, the technology is being developed by the Microfluidics Innovation Center and Elvesys, an entrepreneur-led company with a history of 10 spin-offs, suggesting a commercialization-focused IP strategy.
The technology supports the 'Three Rs principle' and aligns with legislative goals to reduce animal testing by 2035.
The project period runs from 2023-05-01 to 2025-04-30, with the goal of producing a demonstrator for beta testing by the end of the term.
The consortium is highly lean and commercially oriented, consisting of 2 partners from France. It is 100% industry-led by SMEs, specifically the Microfluidics Innovation Center and Elvesys. This structure minimizes academic lag and leverages Elvesys's track record of 15 commercial instruments and 10 spin-offs, suggesting a high probability of rapid market entry.
Contact the Microfluidics Innovation Center in France
Contact us to connect with the GALILEO team for beta testing opportunities.
